| The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance AM Schmalstieg, S Srivastava, S Belkaya, D Deshpande, C Meek, R Leff, ... Antimicrobial agents and chemotherapy 56 (9), 4806-4815, 2012 | 211 | 2012 |
| Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence JG Pasipanodya, D Ogbonna, BE Ferro, G Magombedze, S Srivastava, ... Antimicrobial agents and chemotherapy 61 (11), 10.1128/aac. 01206-17, 2017 | 146 | 2017 |
| Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests S Swaminathan, JG Pasipanodya, G Ramachandran, AK Hemanth Kumar, ... Clinical Infectious Diseases 63 (suppl_3), S63-S74, 2016 | 127 | 2016 |
| Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis S Srivastava, G Magombedze, T Koeuth, C Sherman, JG Pasipanodya, ... Antimicrobial agents and chemotherapy 61 (8), 10.1128/aac. 00751-17, 2017 | 107 | 2017 |
| Levofloxacin pharmacokinetics/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis D Deshpande, JG Pasipanodya, SG Mpagama, P Bendet, S Srivastava, ... Clinical Infectious Diseases 67 (suppl_3), S293-S302, 2018 | 104 | 2018 |
| Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis D Deshpande, S Srivastava, M Chapagain, G Magombedze, KR Martin, ... Science Advances 3 (8), e1701102, 2017 | 77 | 2017 |
| d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal D Deshpande, JWC Alffenaar, CU Köser, K Dheda, ML Chapagain, ... Clinical Infectious Diseases 67 (suppl_3), S308-S316, 2018 | 70 | 2018 |
| Tigecycline is highly efficacious against Mycobacterium abscessus pulmonary disease BE Ferro, S Srivastava, D Deshpande, JG Pasipanodya, D van Soolingen, ... Antimicrobial agents and chemotherapy 60 (5), 2895-2900, 2016 | 70 | 2016 |
| Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular … D Deshpande, S Srivastava, C Meek, R Leff, T Gumbo Antimicrobial agents and chemotherapy 54 (5), 1728-1733, 2010 | 70 | 2010 |
| Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium–intracellulare complex disease JG Pasipanodya, D Ogbonna, D Deshpande, S Srivastava, T Gumbo Journal of Antimicrobial Chemotherapy 72 (suppl_2), i3-i19, 2017 | 69 | 2017 |
| Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection D Deshpande, S Srivastava, C Meek, R Leff, GS Hall, T Gumbo Antimicrobial agents and chemotherapy 54 (6), 2534-2539, 2010 | 60 | 2010 |
| Failure of the amikacin, cefoxitin, and clarithromycin combination regimen for treating pulmonary Mycobacterium abscessus infection BE Ferro, S Srivastava, D Deshpande, JG Pasipanodya, D van Soolingen, ... Antimicrobial Agents and Chemotherapy 60 (10), 6374-6376, 2016 | 58 | 2016 |
| A faropenem, linezolid, and moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children: FLAME path on the Milky Way D Deshpande, S Srivastava, E Nuermberger, JG Pasipanodya, ... Clinical Infectious Diseases 63 (suppl_3), S95-S101, 2016 | 49 | 2016 |
| Amikacin pharmacokinetics/pharmacodynamics in a novel hollow-fiber Mycobacterium abscessus disease model BE Ferro, S Srivastava, D Deshpande, CM Sherman, JG Pasipanodya, ... Antimicrobial agents and chemotherapy 60 (3), 1242-1248, 2016 | 49 | 2016 |
| A long-term co-perfused disseminated tuberculosis-3D liver hollow fiber model for both drug efficacy and hepatotoxicity in babies S Srivastava, JG Pasipanodya, G Ramachandran, D Deshpande, ... EBioMedicine 6, 126-138, 2016 | 48 | 2016 |
| Concentration-dependent synergy and antagonism of linezolid and moxifloxacin in the treatment of childhood tuberculosis: the dynamic duo D Deshpande, S Srivastava, E Nuermberger, JG Pasipanodya, ... Clinical Infectious Diseases 63 (suppl_3), S88-S94, 2016 | 43 | 2016 |
| Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: Goldilocks S Srivastava, D Deshpande, J Pasipanodya, E Nuermberger, ... Clinical Infectious Diseases 63 (suppl_3), S102-S109, 2016 | 43 | 2016 |
| Amikacin optimal exposure targets in the hollow-fiber system model of tuberculosis S Srivastava, C Modongo, CW Siyambalapitiyage Dona, JG Pasipanodya, ... Antimicrobial agents and chemotherapy 60 (10), 5922-5927, 2016 | 42 | 2016 |
| Linezolid for infants and toddlers with disseminated tuberculosis: first steps D Deshpande, S Srivastava, JG Pasipanodya, SJ Bush, E Nuermberger, ... Clinical Infectious Diseases 63 (suppl_3), S80-S87, 2016 | 41 | 2016 |
| Antibacterial and sterilizing effect of benzylpenicillin in tuberculosis D Deshpande, S Srivastava, P Bendet, KR Martin, KN Cirrincione, PS Lee, ... Antimicrobial Agents and Chemotherapy 62 (2), 10.1128/aac. 02232-17, 2018 | 40 | 2018 |
Shashikant SrivastavaAssociate Professor Department of Medicine, UT Tyler School of MedicineVerified email at uthct.edu